Rubicon Research IPO Details
| Detail | Description |
|---|---|
| IPO Date | October 9, 2025 to October 13, 2025 |
| Listing Date | [.] |
| Face Value | ₹ 1 per share |
| Issue Price Band | ₹ 461 to ₹ 485 per share |
| Lot Size | 30 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 2,84,02,040 shares (aggregating up to ₹ 1,377.5 Cr) |
| Fresh Issue(Ex Market Maker) | 1,03,09,278 shares (aggregating up to ₹ 500 Cr) |
| Offer for Sale | 1,80,92,762 shares of ₹1 (aggregating up to ₹ 877.5 Cr) |
| Employee Discount | ₹ 48 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 15,44,37,251 shares |
| Share Holding Post Issue | 16,47,46,529 shares |
About Rubicon Research IPO
Rubicon Research IPO is a book-built issue of INR 1,377.50 crores. The issue consists of a combination of a fresh issue of 0.13 crore shares and an offer for sale of 1.81 crore shares. The price band is set at INR 461 to INR 485 per share, and the lot size for an application is 30 shares. The minimum investment required by a retail investor is INR 14,550 (30 shares). The IPO opens on October 9, 2025, and closes on October 13, 2025. It will list on BSE and NSE with a tentative listing date of October 16, 2025.
Company Background
Rubicon Research Limited, incorporated in 1999, is a specialty pharmaceutical company focused on developing, manufacturing, and commercializing differentiated formulations. As of June 30, 2025, the company has 72 active ANDA and NDA products approved by the US FDA, with 66 commercialized products contributing USD 195 million in Fiscal 2024 within a US generic pharmaceutical market of USD 2,455.7 million. Rubicon markets over 350 SKUs to 96 customers, including major wholesalers that dominate US drug distribution.
Conclusion
The Rubicon Research IPO presents an opportunity for investors to invest in a fast-growing Indian pharmaceutical company with a strong focus on innovation and product diversification. Its robust R&D capabilities, diverse product portfolio, and presence in the US generic market make it a recognizable player in the industry. Backed by a strong revenue record, cost-effective manufacturing, and an experienced management team, Rubicon is well-positioned for sustained long-term value creation.
Rubicon Research IPO Financial Information
Latest Revenue
356.95
₹ Crore
Profit After Tax
43.3
₹ Crore
Net Worth
593
₹ Crore
Total Borrowing
495.78
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 30 Jun 2025 | 1,647.6 | 356.95 | 43.3 | 593 | 495.78 | ||||
| 31 Mar 2025 | 1,451.43 | 1,296.22 | 134.36 | 540.98 | 393.17 | ||||
| 31 Mar 2024 | 1,109.49 | 872.39 | 91.01 | 385 | 396.41 | ||||
| 31 Mar 2023 | 749.7 | 419 | -16.89 | 286.38 | 317.91 | ||||
| Amount in ₹ Crore | |||||||||
Rubicon Research Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 29.02% |
| ROCE | 26.45% |
| Debt/Equity | 0.73 |
| RoNW | 29.02% |
| PAT Margin | 10.37% |
| EBITDA Margin | 20.67% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 8.70 | - |
| P/E (x) | - | - |
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Fastest-growing Indian pharmaceutical company that supports a strong commercial pipeline and robust sales.
Experienced management and cost-effective manufacturing.
Download regulatory filings
Rubicon Research IPO Timeline
| IPO Open Date | Thu, Oct 9, 2025 |
| IPO Close Date | Mon, Oct 13, 2025 |
| Tentative Allotment | Tue, Oct 14, 2025 |
| Initiation of Refunds | Wed, Oct 15, 2025 |
| Credit of Shares to Demat | Wed, Oct 15, 2025 |
| Tentative Listing Date | Thu, Oct 16, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Mon, Oct 13, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | 30 | ₹14,550 |
| Individual investors (Retail) (Max) | 13 | 390 | ₹1,89,150 |
| S-HNI (Min) | 14 | 420 | ₹2,03,700 |
| S-HNI (Max) | 68 | 2,040 | ₹9,89,400 |
| B-HNI (Min) | 69 | 2,070 | ₹10,03,950 |